LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the launch of a ...
Compass Pathways is planning to share 26-week data from the COMP005 study once all patients have completed the initial six-week portion of another study dubbed ...
Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results